Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data from two pipeline programs that modulate the hepcidin pathway will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition
CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data from two pipeline programs that modulate the hepcidin pathway will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, which will be held virtually December 5-8, 2020. Details of the presentations are as follows: Abstract Number: 1690 Abstract Number: 2599 Full abstracts are currently available through the ASH conference website: www.hematology.org/Annual-Meeting/Abstracts/. About Disc Medicine
View original content to download multimedia:http://www.prnewswire.com/news-releases/disc-medicine-to-present-at-the-virtual-62nd-american-society-of-hematology-annual-meeting-301185107.html SOURCE Disc Medicine |